NUVB Nuvation Bio Inc.
Company Analysis
Latest News
🟢 Nuvation Bio Inc. is trading 5.3% up today after advancing IBTROZI and safusidenib trials and regulatory filings
Nuvation Bio Inc. is trading 5.3% up at $5.86 after announcing the advancement of clinical trials and regulatory filings for its lead candidates, IBTROZI and...
🟢 Nuvation Bio Inc. is trading 5.9% up today as it rebounds from post-rally consolidation
Nuvation Bio Inc. is trading 5.9% up today at $5.04, rebounding after a brief pullback and consolidation phase earlier this week. • The stock is regaining...
🔴 Nuvation Bio Inc. is trading 6.7% down today on profit-taking following a recent analyst-driven rally
Nuvation Bio Inc. is trading 6.7% down at $4.60 in pre-market action as the stock undergoes consolidation following a sharp rally earlier in the week. • The...
🔴 Nuvation Bio Inc. is trading 5.5% down today on profit-taking following a sharp post-upgrade rally
Nuvation Bio Inc. is trading 5.5% down at $4.66 as the stock undergoes consolidation following a significant rally driven by analyst optimism. • The stock...
🟢 Nuvation Bio Inc. is trading 13.3% up today as RBC Capital hikes price target to $20
Nuvation Bio Inc. is trading 13.3% up at $5.44, rebounding sharply from last week’s pullback as momentum continues following a major analyst upgrade. • RBC...
Nuvation Bio Pulls Back After RBC's Blockbuster $20 Target — Can a Brain Cancer Drug Justify a 4x Rally?
Shares of Nuvation Bio (NUVB) are slipping further in pre-market trading at $4.73, down 1.9%, as profit-taking extends following one of the most aggressive...
🔴 Nuvation Bio Inc. is trading 5.5% down today as it pulls back from a recent analyst-driven rally
Nuvation Bio Inc. is trading at $4.88 (5.5% down) today, giving back a portion of its sharp gains following a recent bullish analyst call. • RBC Capital...
🟢 Nuvation Bio Inc. is trading 0.4% up today after RBC Capital raised its price target to $20
Nuvation Bio Inc. is trading at $5.19 (0.4%) up today after RBC Capital raised its price target to $20, citing optimism around its glioma drug potential. •...
Nuvation Bio Price Target Raised to $20 by RBC Capital on Glioma Drug Potential
RBC Capital increased its price target for Nuvation Bio Inc. to $20.00 from $13.00. The firm reaffirmed its "Outperform" rating on the stock. The revision...
Nuvation Bio Surges 13% on Conference Buzz, but Can a Single Cancer Drug Justify the Climb?
Shares of Nuvation Bio (NUVB) jumped 13.4% to $5.35 on Thursday, extending a rally that began after CEO David Hung and CFO Philippe Sauvage delivered a...
🟢 Nuvation Bio Inc. is trading 13.4% up today after positive Jefferies conference commentary
Nuvation Bio Inc. is trading 13.4% up today at $5.35, extending momentum following management's participation in a fireside chat at the Jefferies Global...
🟢 Nuvation Bio Inc. is trading 7.94% up, likely boosted by positive commentary at Jefferies Healthcare Conference
Nuvation Bio Inc. (NUVB) is trading 7.94% higher at $5.09 in live trading, with the upward momentum appearing to be driven by investor sentiment following a...